ACUTE GAIN IN MINIMAL LUMEN AREA FOLLOWING IMPLANTATION OF EVEROLIMUS-ELUTING ABSORB BIODEGRADABLE VASCULAR SCAFFOLDS OR XIENCE METALLIC STENTS: INTRAVASCULAR ULTRASOUND ASSESSMENT FROM THE ABSORB II TRIAL  by Cequier, Angel et al.
TCT@ACC-i2: Interventional Cardiology
A1723
JACC March 17, 2015
Volume 65, Issue 10S
aCUte Gain in minimal lUmen area FollowinG implantation oF everolimUs-
elUtinG absorb biodeGradable vasCUlar sCaFFolds or xienCe metalliC stents: 
intravasCUlar UltrasoUnd assessment From the absorb ii trial
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 10:00 a.m.-10:45 a.m.
Session Title: Coronary I
Abstract Category: 34. TCT@ACC-i2: Coronary Intervention: Devices
Presentation Number: 2100-284
Authors: Angel Cequier, Yuki Ishibashi, Hector Garcia Garcia, Yoshinobu Onuma, Patrick W. Serruys, Hospital Bellvitge, Barcelona, Spain, 
Erasmus MC, Rotterdam, The Netherlands
background:  According to a non-randomized comparison, less acute gain has been documented on angiography after Absorb scaffold 
implantation. However, there have been no true comparative randomized data. The aim of this study was to compare by intravascular 
ultrasound (IVUS) the acute gain at the site of pre-procedural minimal lumen area of the Absorb scaffold and the Xience stent and to 
identify the factors contributing to the acute performance of these devices.
methods:  In the randomized ABSORB II trial, 445 patients with 480 lesions were analyzed by intravascular ultrasound (IVUS) at pre- 
and post-procedure. Comparison of minimal lumen area between pre- and post-procedure was performed at the same site by matching 
baseline and post-procedural IVUS pullbacks.
results:  Acute gain in lumen area at the site of pre-procedural minimum lumen area was significantly larger in the Xience arm than the 
Absorb arm (4.27 mm2 vs. 3.46 mm2, p<0.001), while lesion morphology and procedural strategy including pre-dilation before IVUS, 
maximal diameter of device and frequency of post-dilatation after device implantation were comparable. Nominal diameter of the post-
dilatation balloon, pressure during post-dilatation and expected balloon diameter were significantly smaller in the Absorb arm than those 
of the Xience arm (3.16 vs. 3.28 mm, p=0.01, 15.3 vs. 16.7 atm., p=0.001, 3.25 vs. 3.40 mm, p=0.001, respectively). In a multivariate 
analysis, the use of the Absorb scaffold was an independent predictor (OR: 3.232, 95% CI: 1.877 to 5.564, p < 0.001) for less acute gain 
(8.46 mm2 and expected balloon diameter > 3.31mm of the last balloon were protective (OR:0.205, 95% CI: 0.074 to 0.569, p = 0.002; OR: 
0.187, 95% CI: 0.113 to 0.308, p < 0.001, respectively).
Conclusion:  Absorb scaffold showed less acute gain at the site of pre-procedural minimal lumen area than Xience. although he use of a 
post dil balloon with a large size (>3.31mm) have prevented suboptimal expansion in the Absorb arm. Therefore, the BRS technology may 
require more aggressive procedural strategies to achieve equivalent acute gain at the site of pre-procedural minimal lumen area during the 
implantation of Absorb scaffolds.
